FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
MONDAY, June 20, 2022 -- Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbVie.
Approved dosing for...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news